Navigation Links
Penn Dental Medicine, CHOP Team Show HIV/AIDS Drugs Interfere with Brain's 'Insulation'

PHILADELPHIA, Jan. 18 2016 /PRNewswire/ -- Antiretroviral therapies (ART) have enabled people with HIV/AIDS to live much longer lives, essentially transforming the disease into a chronic condition. Yet concerns for these patients remain. Up to half of people with HIV on these drug regimens have some sort of cognitive impairment, such as memory loss or problems with executive functioning, despite the virus being almost undetectable in their bodies.

In a new study, researchers from Penn Dental Medicine and The Children's Hospital of Philadelphia teamed up to investigate the underlying reasons for these impairments. They found that commonly used antiretroviral medications (protease inhibitors Ritonavir and Lopinavir) disrupted the differentiation of oligodendrocytes, crucial brain cells that manufacture myelin, the fatty material that serves to insulate neurons, helping them transmit signals in the brain fast and efficiently.

This disruption, the researchers said, may be responsible for some of the cognitive problems that HIV patients experience, and point to a need for rethinking how HIV drugs are designed and prescribed, particularly for children on ART, in whom myelin is still forming at high rates.

"Pharmaceutical companies have done an amazing job developing drugs to make HIV patients live longer, but we're not done," said Kelly L. Jordan-Sciutto, professor and chair of Penn Dental Medicine's Department of Pathology, who co-led the research with Judith B. Grinspan, a research scientist at CHOP and professor of neurology at Penn's Perelman School of Medicine. "The message we want to get out there is that we want to make these patients' lives better while they are on ART."

The research was published this November in the Journal of Neuropathology and Experimental Neurology.

The researchers have yet to determine a mechanism by which myelin protein levels are altered with ART, but are investigating a number of avenues. They are also evaluating how different HIV medications can affect oligodendrocyte and myelin formation, as the recommended drug cocktails frequently change.

The implications of these findings may be particularly important for pediatric patients, some of whom may have been on ART from birth. Since HIV-infected children exhibit higher rates of neurocognitive disorders such as seizures, depression, and ADHD, the researchers stress that a revised look at treatments for pediatric patients may be warranted, or an additional therapy to prevent the white matter loss in both adults and children could be developed to go hand in hand with the ART.

Beth Adams

SOURCE Penn Dental Medicine
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference
2. Heska Corporation to Present at the Stifel Dental & Veterinary Conference
3. Stanley Bergman Delivers Commencement Address At Stony Brook School Of Dental Medicine
4. Umbie DentalCare - Multiple Opportunities One Solutions
5. GRW bearing lubrication tests yield maximum wear life for medical and dental instruments
6. SmileBest Dental & Orthodontics Opens Their First Office in Hurst, Texas
7. Henry Schein Dental And American Dental Hygienists Association Host "Dream Center" To Mark 100th Anniversary Of Profession
8. Rises to Top as Discount Dental Supply Leader
9. Global Dental Restorative Supplies Industry
10. Global Dental Orthodontic Supplies Industry
11. Henry Schein Chairman Of The Board & CEO Receives Centennial Recognition Award For Extraordinary Commitment To The National Dental Association
Post Your Comments:
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
Breaking Medicine News(10 mins):